In another study investigating ERBB3 (HER3) over-expression in relation to ARPI resistance in castration-sensitive disease, bulk RNA-seq of approximately 900 treatment-naïve tumors uncovered ERBB3 over-expression in approximately 9% of castration-sensitive prostate cancers, enriched in African and Asian ancestry groups. This evidence concerns the gene ERBB3 and prostate cancer.